<DOC>
	<DOCNO>NCT01066715</DOCNO>
	<brief_summary>The study hypothesis XOMA 052 improves glycemic control subject Type 2 Diabetes . Study X052078 design establish efficacious dose ( ) future study base improvement HbA1c .</brief_summary>
	<brief_title>Safety Efficacy XOMA 052 Subjects With Type 2 Diabetes Mellitus Stable Metformin Monotherapy</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Diagnosed T2D ( disease duration ≥ 6 month ) HbA1c ≥ 6.8 % ≤ 10.0 % Have stable regimen metformin monotherapy least 12 week prior Day 0 Willingness maintain stable diet exercise regime throughout study Willingness maintain current doses/regimens vitamin dietary supplement end study Uncontrolled hypertension History malignancy within 5 year History allergic anaphylactic reaction humanize murine monoclonal antibody Advanced stage heart failure ( New York Heart Association [ NYHA ] class 3 4 ) Clinically significant uncontrolled arrhythmias History tuberculosis Active leg , foot , decubitus ulcer Any significant inflammatory , rheumatologic , systemic autoimmune disease History chronic infection History symptom demyelinate disease Major surgery within 3 month Female subject pregnant , plan become pregnant Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>Type 2</keyword>
	<keyword>Mellitus</keyword>
</DOC>